Santen Pharmaceutical (OTCMKTS:SNPHY) Sets New 1-Year High – What’s Next?

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) reached a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $13.9250 and last traded at $13.90, with a volume of 4301 shares. The stock had previously closed at $13.4850.

Analyst Ratings Changes

Separately, Zacks Research raised shares of Santen Pharmaceutical to a “hold” rating in a research report on Monday, April 13th. One equities research analyst has rated the stock with a Hold rating, According to MarketBeat.com, the company currently has an average rating of “Hold”.

Santen Pharmaceutical Price Performance

The company has a market capitalization of $4.48 billion and a P/E ratio of 0.10. The firm has a fifty day moving average price of $11.80 and a 200-day moving average price of $11.25.

About Santen Pharmaceutical

Santen Pharmaceutical Co, Ltd. is a Japan‐based specialty pharmaceutical company focused exclusively on ophthalmology. Headquartered in Osaka, Santen engages in the research, development, manufacture and marketing of prescription and over‐the‐counter products for the diagnosis and treatment of eye diseases. Its core product portfolio includes therapies for glaucoma, dry eye, retinal disorders, uveitis and post‐operative care, as well as surgical equipment and diagnostic agents designed to support comprehensive eye care.

With roots tracing back to the late 19th century, Santen has grown from a domestic manufacturer to a global ophthalmic specialist.